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and warfarin do not differ significantly in real-world rates of composite stroke 
and systemic embolism and major, intracranial, or GI bleeding. Rivaroxaban was 
associated with significantly fewer VTE events and better treatment persistence 
compared with warfarin.
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Objectives: Statins have been shown to significantly reduce the cardiovascular 
risk. In recent studies, high potency statins have been associated with elevated fast-
ing plasma glucose (FPG) and glycated hemoglobin A1c (HbA1c) level. Rosuvastatin is 
widely prescribed statin medication for treating dyslipidemia. A systematic review 
was conducted to examine rosuvastatin’s effect on glycemia levels and quality of 
life. MethOds: Double-blind, randomized, clinical trials reporting changes in FBG, 
HbA1C, incidence of new onset diabetes and quality-adjusted life years (QALYs) 
with rosuvastatin therapy were included in this systematic review. Studies that 
were open label, non-randomized, observational, with combination therapies; case 
reports, less than four weeks duration and published in other than English language 
were excluded. Search was performed using MEDLINE, PubMed, Google scholar 
and Cochrane Central Register for Controlled Trials (CENTRAL) using key words 
and MeSH terms through July 2013. Results: From the total of 535 clinical and 
16 health outcomes studies, three clinical (n = 24,714; rosuvastatin arm = 12,332) 
and four outcomes studies met the inclusion criteria. The mean study follow up 
ranged from 1.9 to 3.9 yrs. Incidence of diabetes was reported in 595 (4.8%) patients 
in rosuvastatin arm compared to 519 (4.2%) in placebo arm (RR 1.15, 95% CI 1.026-
1.291). Only one study reported median change in FPG (4mg/dl) and HbA1c (0.2%) 
on two years of therapy. QALYs gained over a lifetime with rosuvastatin therapy 
in patients with Framingham risk score (FRS) ≤ 10% was estimated 0.14, FRS> 10% 
0.33, and with FRS> 20% 0.42 per patient, respectively. Rosuvastatin therapy for pri-
mary or secondary prevention of cardiovascular events in a high-risk population 
showed more QALYs gained compared to low-risk patients from the health system 
perspective. cOnclusiOns: Overall, there was an increase in new onset diabetes 
with rosuvastatin therapy. However, the benefit of reducing cardiovascular risk and 
improved quality of life with rosuvastatin therapy outweighs the risk of diabetes.
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Objectives: Statins have been shown to significantly reduce the risk of heart attack 
and heart disease. However, in recent studies, they were found to raise blood sugar 
levels resulting in diabetes. Atorvastatin is most widely prescribed medication 
among statins for treating hypercholesterolemia. A systematic review of randomized 
clinical trials (RCTs) was conducted to evaluate Atorvastatin’s effect on glycemia 
levels and incidence of diabetes. MethOds: MEDLINE, PubMed, Google Scholar and 
Cochrane Central Register of Controlled Trials (CENTRAL) were searched through 
July 2013. RCTs that evaluated Atorvastatin in patients with hypercholesterolemia 
and reported at least one of the following: glycated hemoglobin (HbA1c), fasting 
blood glucose and new onset of diabetes were included. Studies that were open 
label, shorter than four weeks, and published in other than English language were 
excluded. The primary outcome measures were change from baseline in fasting 
glucose, HbA1c level and/or development of diabetes. Results: The final analysis 
of this systematic review included four RCTs out of 104 full text articles retrieved 
that met our inclusion criteria. The sample size in these studies ranged from 3,806 
to 7,461 with a follow up ranging from 2 to 4.9 years. The change from baseline 
fasting blood glucose ranged between 8 to 10.6mg/dL and the incidence of new 
onset diabetes reported ranged from 4.2% to 9.3%. Atorvastatin doses studied were 
40 and 80mg. Studies included in this systematic review showed high degrees of 
heterogeneity in data reporting and analyses. cOnclusiOns: Use of Atorvastatin 
in these studies showed a significant increase in fasting blood glucose and devel-
opment of diabetes. However, high degree of study heterogeneity limited finding’s 
generalizability to a larger population. Atorvastatin’s cardiovascular benefit still 
clearly outweighs the potential risk of reported incident diabetes. Physicians should 
weigh the risks and benefits when prescribing Atorvastatin for their patients in 
treating hypercholesterolemia.
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Objectives: To estimate the risk of angioedema and angioedema related side-
effects caused by the use of dipeptidylpeptidase inhibitors(DPP-4), angiotensin con-
verting enzyme inhibitors (ACEI) and their interaction in patients suffering from 
diabetes and/or hypertension. MethOds: A retrospective analysis employing a 
case control design was performed using Mississippi Medicaid fee-for-service data 
from January 1st 2008 to December 31st 2012. Beneficiaries using oral anti-diabetics 
or anti-hypertensives were included in the study. Angioedema was identified using 
ICD-9-CM codes in the medical claims dataset. Beneficiaries with and without an 
incidence of angioedema were matched based on age, sex, race and whether they 
had diabetes or hypertension. Drug use was analyzed in the 180 days before the 
incidence of angioedema. Results: A total of 1,109 cases and 1,109 controls were 
obtained. Women comprised nearly 70% of the population after matching the cases. 
62% of the population was African American and nearly 30% was Caucasian. 8% of 
the population had diabetes only and approximately 15% had both diabetes and 
hypertension. 77% of the population was identified as having only hypertension. 
Only seven controls and none of the cases were found to be using DPP-4s, either 
alone or along with ACEI, in the study period. None of the patients on DPP-4s had 
an incidence of angioedema. No evidence was found to support the hypothesis that 
DPP-4s increase the incidence of angioedema when used alone or in combination 
with ACEIs. cOnclusiOns: All cases of angioedema that were found in patients 
who were using DPP-4s, did not have the temporal association that is required to 
establish some degree of correlation, if not causality. However, this study can only 
predict that if there were cases of DPP-4s induced angioedema, they could not be 
identified. Any chances of angioedema caused by DPP-4s themselves or an interac-
tion between DPP-4s and ACEIscould not be established by this study.
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Objectives: Atrial Fibrillation (AF) is the most common cardiac arrhythmia for 
adults. It may cause severe health problems, and is associated with significant mor-
bidity and resulting high mortality. We investigated the hazard ratios (HR) of major 
adverse cardiovascular events (MACE) between new-diagnosed AF (NDAF) with dif-
ferent comorbidities and non-AF subjects without any comorbidity. MethOds: 
Data extracted from the National Health Insurance Research Database for this 
observational retrospective cohort study between 2006 and 2010. Using 1 to 4 pro-
pensity score matching method, it resulted with 3,737 NDAF patients and 14,948 
non-AF patients. The baseline comorbidity of hypertension (HTN), diabetes mellitus 
(DM), dyslipidemia, gender, and age (65 years) were used in the matching process. 
Log rank test and Cox proportion hazard models were used to estimate and to 
predict the HR of risk factors associated with MACE. Results: After propensity 
score matching, there was no baseline demographic characteristics difference in 
patients between NDAF and non-AF groups. There is a statistical significance of 
MACE between NDAF and non-AF with HR = 3.4, 95% C.I.of (3.2, 3.6), p < 0.0001. 
When comparing to the non AF subjects without any comorbidity, the HRs were 
8.45, 8.71, 12.27, and 12.42 for NDAF alone, NDAF with Dyslipidemia, DM, and HTN, 
respectively. All p values < 0.0001. Moreover, the HR of MACE between NDAF with 
all three comorbidities comparing to non-AF without any comorbidity resulted in 
a higher HR of 13.54. cOnclusiOns: This study has demonstrated that NDAF risk 
alone is highly associated with a higher risk of MACEs as compared to those without 
AF. After adjusting age and gender, NDAF, with known comorbidity HTN, DM and 
Dyslipidemia, will have even higher risk for MACE outcome.
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Objectives: Previous published criticisms of safety studies based on secondary 
databases suggest significant methodological flaws, including substantial missing 
data, biased diagnoses, outcome under-reporting, and poor transparency in data 
analytics. Clalit Health Services (CHS) is a payer-provider comprehensive health 
fund, with 4 million members. The administrative and clinically-oriented CHS 
database encompasses a decade of integrated inpatient, outpatient, laboratory and 
pharmacy data. Leveraging published safety studies of the association between 
the risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) 
among Oral Contraceptives (OCs) users of differing progestogens, we tested if the 
comprehensiveness of the CHS’ EMR database could overcome prior criticisms of 
secondary database-conducted safety studies. MethOds: Data for all CHS female 
members aged 15-49 were accessed. A retrospective cohort study design 1.2008-
6.2013 identified new OC users in 2008, following-up until study period end. VTE and 
ATE incidence was determined and Cox-regression models estimated time-to-event 
across OC groups. RESULTSAmong 755,824 women in 2008, 94,792 new OC users were 
identified using comprehensive pharmacy dispensing data. Monthly demographic 
data and periodically measured clinical data (like BMI and smoking) are recorded 
following strict quality measures, resulting in only 9.5% missing smoking status 
and 2.1% missing BMI values among this sample. Community-based and hospital 
EMRs are centrally collated. Cardiovascular outcomes were validated via patient 
file review. As VTE-related hospitalization is independent of gynecologist referral 
we expect minimal bias on this account. Symptomatic effects requiring interven-
tion are fully reported as cost-related procedures. Out-of-pocket copayments are 
minimal, not predisposing against referrals. Transparency and quality are assured 
by detailed epidemiology and biostatistics protocols followed explicitly, statistical 
programming using cross-checked validated code and peer-reviewed statistical 
analyses cOnclusiOns: As a result of unique historical circumstances and policy 
decisions, Clalit’s comprehensive and integrated data warehouse was able to over-
come previously identified flaws in secondary databases for use in safety studies.
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Objectives: The risk of venous thromboembolism (VTE) associated with antip-
sychotic use has been examined in a variety of populations but not in postmen-
opausal women prone to VTE. This study aimed to assess the VTE risk related 
to antipsychotics after menopause. MethOds: A nested case-control study of 
271,198 women aged ≧ 50 years was conducted analyzing data from the Taiwan 
